Episode Details
Back to Episodes
DiagnosTear Targets Needle-Free Blood Testing With Eye Scan Tech | DiagnosTear Technologies (CSE: DTR)
Description
In this episode of The Watchlist, listeners hear from DiagnosTear Technologies Chairman Yaacov Michlin about the company’s exclusive global licensing agreement for the Clarify eye imaging platform — a technology aiming to enable blood analysis through a simple, non-invasive eye scan.
The discussion explores how DiagnosTear plans to commercialize the platform, the AI and computer vision technology behind the system, and why management believes this innovation could reshape diagnostics and point-of-care healthcare worldwide.
This discussion covers:
- DiagnosTear’s exclusive global licensing agreement for the Clarify platform
- How eye imaging technology could replace certain traditional blood tests
- The AI and computer vision technology powering the platform
- The commercial opportunity in point-of-care diagnostics
- Why management believes this could represent a major shift in healthcare testing
This podcast is made in partnership with DiagnosTear Technologies. The content is for informational purposes only and should not be considered investment advice. Please do your own due diligence before making any investment decisions. For our full disclaimer, visit: https://stockhouse.com/legal/disclaimer
#DiagnosTear #DTR #Biotech #HealthcareInnovation #MedicalTechnology #Investing #PointOfCare
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.